Endocrine side-effects of anti-cancer drugs: Thyroid effects of tyrosine kinase inhibitors

European Journal of Endocrinology

Volumn 171, Issue 3, 2014, Pages R91-R99

  Illouz, Frédéric ^a   Braun, Doreen ^b   Briet, Claire ^c   Schweizer, Ulrich ^b   Rodien, Patrice ^a,d,e  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF BONN   (Germany)

^c BICÊTRE HOSPITAL   (France)

^d INSERM   (France)

^e Universitéd'Angers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; DASATINIB; IMATINIB; LEVOTHYROXINE; MOTESANIB; NILOTINIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROID HORMONE; VANDETANIB; PROTEIN KINASE INHIBITOR;

ANOREXIA; BODY WEIGHT DISORDER; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DYSGEUSIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY CARCINOMA; ONCOLOGIST; PATHOPHYSIOLOGY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; THYROID DISEASE; THYROID FUNCTION TEST; THYROID HORMONE METABOLISM; THYROID HORMONE SYNTHESIS; THYROID MEDULLARY CARCINOMA; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENDOCRINE SYSTEM; METABOLISM; METHODOLOGY; THYROID GLAND;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOCRINE SYSTEM; HUMANS; PROTEIN KINASE INHIBITORS; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; THYROID HORMONES;

EID: 84907215846     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0198     Document Type: Review

References (62)

1. Croce CM. Oncogenes and cancer. New England Journal of Medicine 2008 358 502-511. (doi:10.1056/NEJMra072367)
2. Schöffski P, Wolter P, Himpe A, Dychter SS, Abraham S, Baum C, Peren H, Wildiers H, Bex M & Dumez H. Sunitinib-related thyroid dysfunction: a single center retrospective and prospective evaluation. Journal of Clinical Oncology 2006 24 (18S) 3092. (http://meeting.ascopubs.org/cgi/content/short/24/18-suppl/3092)
3. Desai J, Yassa L, Marqusee E, George S, FratesMC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine 2006 145 660-664. (doi:10.7326/0003-4819- 145-9-200611070-00008)
4. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT & Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics 2005 78 433-438. (doi:10.1016/j.clpt.2005.06.010)
5. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Annals of Oncology 2012 23 714-721. (doi:10.1093/annonc/mdr275)
6. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, Beck-Peccoz P & Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Journal of Clinical Endocrinology and Metabolism 2007 92 3531-3534. (doi:10.1210/jc.2007-0586)
7. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M & Hershman JM. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007 17 351-355. (doi:10.1089/thy.2006.0308)
8. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 2011-2019. (doi:10.1016/S0140-6736(07)61865-0)
9. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R & Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 2007 99 81-83. (doi:10.1093/jnci/djk008)
10. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P & Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. British Journal of Cancer 2008 99 448-454. (doi:10.1038/sj.bjc.6604497)
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA et al. Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009 27 3584-3590. (doi:10.1200/JCO.2008.20.1293)
12. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology 2012 30 1371-1377. (doi:10.1200/JCO.2011. 36.4133)
13. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine 2013 369 722-731. (doi:10.1056/NEJMoa1303989)
14. Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, Thielen B & Herrmann E. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World Journal of Urology 2011 29 807-813. (doi:10.1007/s00345-010-0627-2)
15. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 501-513. Erratum in New England Journal of Medicine 2011 364 1082. (doi:10.1056/NEJMoa1003825)
16. Grossmann M, Premaratne E, Desai J & Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology 2008 69 669-672. (doi:10.1111/j.1365-2265.2008.03253.x)
17. Chen SY, Kao PC, Lin ZZ, Chiang WC & Fang CC. Sunitinib-induced myxedema coma. American Journal of Emergency Medicine 2009 27 370. (doi:10.1016/j.ajem.2008.07.012)
18. Lele AV, Clutter S, Price E & De Ruyter ML. Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature. Journal of Clinical Anesthesia 2013 25 47-51. (doi:10.1016/j.jclinane.2012.07.001)
19. Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC & Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. Journal of Chemotherapy 2012 24 221-225. (doi:10.1179/1973947812Y.0000000022)
20. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J & Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology 2008 19 265-268. (doi:10.1093/annonc/mdm483)
21. Clemons J, Gao D, Naam M, Breaker K, Garfield D & Flaig TW. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clinical Genitourinary Cancer 2012 10 225-231. (doi:10.1016/j.clgc.2012. 08.002)
22. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2012 378 1931-1939. Erratum in Lancet 2012 380 1818. (doi:10.1016/S0140-6736(11)61613-9)
23. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, GoreME, Tarazi J, Hariharan S et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncology 2013 14 552-562. (doi:10.1016/S1470- 2045(13)70093-7)
24. Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD & Schulz M. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. European Journal of Cancer 2012 48 974-981. (doi:10.1016/j.ejca.2012.01.036)
25. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH & Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 2011 21 197-202. (doi:10.1089/thy. 2010.0234)
26. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P & Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid 2010 20 1043-1044. (doi:10.1089/thy.2010.0070)
27. Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K & Ing SW. Case of sorafenib-induced thyroid storm. Journal of Clinical Oncology 2013; 13:e262-e264. (doi:10.1200/JCO.2012.46.7142)
28. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ et al. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
29. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M et al. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
30. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 923-931. (doi:10.1530/EJE- 09-0702)
31. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 2011 165 315-322. (doi:10.1530/EJE-11-0129)
32. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW & Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. European Journal of Endocrinology 2012 167 643-650. (doi:10.1530/EJE-12-0405)
33. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2013 30 134-141. Erratum in Journal of Clinical Oncology 2013 31 3049. (doi:10.1200/JCO.2011.35.5040)
34. Verloop H, Smit JW & Dekkers OM. Sorafenib therapy decreases the clearance of thyrotropin. European Journal of Endocrinology 2013 168 163-167. (doi:10.1530/EJE-12-0828)
35. Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 2664-2671. (doi:10.1210/jc.2009-2461)
36. Brassard M, Neraud B, Trabado S, Salenave S, Brailly-Tabard S, Borget I, Baudin E, Leboulleux S, Chanson P, Schlumberger M et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2011 96 2741-2749. (doi:10.1210/jc.2010-2771)
37. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011 29 1067-1074. (doi:10.1200/JCO.2010.29.5717)
38. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011 29 1059-1066. (doi:10.1200/JCO.2010.28.5981)
39. Herbst RS, Sun Y, Eberhardt WE, GermonpréP, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology 2010 11 619-626. (doi:10.1016/S1470-2045(10)70132-7)
40. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T et al. Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 31-42. (doi:10.1056/NEJMoa075853)
41. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 2009 27 3794-3801. (doi:10.1200/JCO.2008.18.7815)
42. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC et al. Cabozantinib in progressive medullary thyroid cancer. Journal of Clinical Oncology 2013 31 3639-3646. (doi:10.1200/JCO.2012.48.4659)
43. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology 2013 31 412-419. (doi:10.1200/JCO.2012.45.0494)
44. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC III, McIver B et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncology 2010 11 962-972. (doi:10.1016/S1470-2045(10)70203-5)
45. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, Braun D, Schweizer U, Arnold R, Dörken B et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010 20 1209-1214. (doi:10.1089/thy.2010.0251)
46. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 2010 362 2251-2259. (doi:10.1056/NEJMoa0912614)
47. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology 2011 12 841-851. (doi:10.1016/S1470- 2045(11)70201-7)
48. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M & Kurokawa M. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. International Journal of Hematology 2011 93 400-402. (doi:10.1007/s12185-011-0790-2)
49. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ & Voest EE. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 3466-3469. (doi:10.1210/jc.2007-0649)
50. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F & Maia AL. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. European Journal of Endocrinology 2008 158 771-772. (doi:10.1530/EJE-08-0006)
51. Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S & Nakamura H. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 2013 23 443-448. (doi:10.1089/thy.2012.0378)
52. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. Journal of Clinical Endocrinology and Metabolism 2011 96 3087-3094. (doi:10.1210/jc. 2011-1172)
53. Makita N, Miyakawa M, Fujita T & Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010 20 323-326. (doi:10.1089/thy.2009.0414)
54. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B & Schöffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 2010 20 317-322. (doi:10.1089/thy. 2009.0125)
55. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology. Heart and Circulatory Physiology 2006 290 H560-H576. (doi:10.1152/ajpheart.00133.2005)
56. Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM & Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. Journal of Clinical Endocrinology and Metabolism 2012 97: E100-E105. (doi:10.1210/jc.2011-1837)
57. Schweizer U & Köhrle J. Function of thyroid hormone transporters in the central nervous system. Biochimica et Biophysica Acta 2013 1830 3965-3973. (doi:10.1016/j.bbagen.2012.07.015)
58. Braun D & Schweizer U. Authentic bosutinib inhibits triiodothyroninetransport by monocarboxylate transporter 8. Thyroid 2014 24 926-927. (doi:10.1089/thy.2013.0660)
59. Campos-Barros A, Meinhold H, Stula M, Müller F, Köhler R, Eravci M, Putzien O & Baumgartner A. The influence of desipramine on thyroid hormone metabolism in rat brain. Journal of Pharmacology and Experimental Therapeutics 1994 268 1143-1152.
60. Roth S, Kinne A & Schweizer U. The tricyclic antidepressant desipramine inhibits T3 import into primary neurons. Neuroscience Letters 2010 478 5-8. (doi:10.1016/j.neulet.2010.04.055)
61. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. Journal of Clinical Endocrinology and Metabolism 2010 95 3758-3762. (doi:10.1210/jc.2009-2507)
62. Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. New England Journal of Medicine 2014 370 1327-1334. (doi:10.1056/NEJMoa1308893)